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We read with great interest the recent paper by Ras-
mussen et al. (1). They reported that the incidence of 
erythema marginatum (EM), a skin rash considered 
to be a primary prodromal manifestation of hereditary 
angioedema (HAE), was as high as 56% and that EM was 
often misdiagnosed as urticaria in the 87 HAE patients 
analysed. The authors also showed that misdiagnosis of 
EM as urticaria delayed the diagnosis of HAE. Their 
findings support those of an earlier study by Magerl et 
al. (2). 
For decades patients with HAE were considered not 
to have urticaria. On the other hand, we have previously 
stated that bradykinin-mediated angioedema cannot be 
ruled out solely on a positive medical history of urticaria 
(3). Rasmussen et al. retrospectively investigated the 
history of urticaria in their cohort. Twenty-two of 87 
(25%) patients with HAE reported at least one episode 
of urticaria. Urticaria was acute, inducible (“physical”), 
or referred to as chronic spontaneous urticaria. Ho-
wever, the majority of the patients (16/22) presented 
urticaria of “unspecified” origin. The precise nature 
of, or factors triggering, urticaria in this particular 
group remain a matter of discussion. However, based 
on these findings and on our clinical experience (3), 
the lifetime incidence of urticaria may be higher in 
patients with HAE than in the general population. We 
therefore strongly question the dogma that “patients 
with HAE do not have urticaria”. Indeed we have seen 
several patients with prodromal manifestations of at-
tacks of angioedema presenting as erythematous and 
oedematous pitting rather than pruritic papules (Fig. 
S11). These observations suggest that some EM may 
present as or even be urticaria. The pathophysiology of 
EM, an odd erythematous rash in the context of a non-
inflammatory condition, is not completely understood. 
Furthermore, there is a lack of data on the incidence of 
urticaria compared with other prodromal skin rashes in 
patients with HAE. This is an issue primarily concer-
ning dermatologists, since they are probably the most 
capable of properly describing various types of skin rash 
in this context. Finally, it is also not clear why only a 
subset of patients with HAE may present with urticaria.
The increased vascular leakage in HAE is mostly due 
to formation of the peptide hormone bradykinin (BK). 
Mouse models have revealed that heparin released from 
allergen-activated mast cells triggers BK production and 
angioedema episodes in a kinin B2 receptor-dependent 
manner (4). Similarly, BK produced by the plasma 
contact system contributes in anaphylaxis and allergic 
diseases to increased vascular permeability, and this 
reaction cascade is also initiated by allergen-stimulated 
mast cells (5). Taken together, these findings indicate 
that oedema in patients with HAE may be precipitated 
by allergen exposure, emphasizing a role of mast cells 
in initiating BK-mediated oedema. They support the 
observation that mast cell-driven urticaria or urticaria-
like manifestations do exist in patients with HAE. The 
lower frequency of allergic diseases in the general 
population (including patients with HAE) when HAE 
has been described could be an explanation for the 
statement that these patients were initially considered 
not to have urticaria. However, physicians must remain 
alert and aware that disease manifestations may be 
modified over time.
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We appreciate the comments from Martin et al. on our 
paper (1). We fully support their message, that bradyki-
nin-mediated angioedema cannot be ruled out based on a 
positive medical history of urticaria. They illustrate this 
statement by photographs of wheals occurring as prodro-
mal manifestations of HAE attacks in 2 of their patients. 
To our knowledge, this is the first report of such 
patients documented by photographs. Theoretically, 
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one way to investigate mast cell activation would be 
to measure serum-tryptase in the initial phase of an at-
tack. However, this test may not be sensitive enough. 
Also, patients with EM do not have elevated tryptase 
levels (6).
Similarly, in our clinical experience, patients with 
another form of bradykinin-related angioedema, namely 
angiotensin-converting enzyme-inhibitor induced angi-
oedema, might present with various rashes including ur-
ticarial eruptions (unpublished data). In addition, within 
this field, there is a clinical dogma that if an urticarial 
eruption is present the angioedema cannot be caused by 
the angiotensin-converting enzyme-inhibitor (7). Tai et 
al. (8), in one of the largest studies on this topic, found 
a rash to be present in almost 8% of patients presen-
ting with angioedema due to angiotensin-converting 
enzyme-inhibitors or angiotensin II-receptor blocking 
agents (personal communication, unpublished data).
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